Pfizer Inc.’s RSV shot produced immune reactions in young adults at higher risk of severe illness just as well as in older people, spurring the company’s plans to apply for wider U.S. approval. A single dose of the vaccine, called Abrysvo, produced a strong immune response in adults ages 18 to 59 with conditions such as asthma, diabetes, or chronic lung disease, Pfizer said. Based on the final-stage trial results, the company plans to ask the Food and Drug Administration to extend the shot’s approval to adults 18 and older. [time-brightcove not-tgx=”true”] RSV, or respiratory syncytial virus, is a flu-like illness that affects elderly adults and babies most severely. The marke
Hence then, the article about young adults may soon be able to get an rsv shot was published today ( ) and is available onTime ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Young Adults May Soon Be Able to Get an RSV Shot )